KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Shares Outstanding (Weighted Average): 2009-2025

Historic Shares Outstanding (Weighted Average) for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Sep 2025 value amounting to $256.4 million.

  • Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) fell 0.66% to $256.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $256.4 million, marking a year-over-year decrease of 0.66%. This contributed to the annual value of $257.5 million for FY2024, which is 0.06% down from last year.
  • Per Vertex Pharmaceuticals' latest filing, its Shares Outstanding (Weighted Average) stood at $256.4 million for Q3 2025, which was down 0.16% from $256.8 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $260.0 million during Q1 2021, and its lowest value of $254.3 million during Q4 2021.
  • In the last 3 years, Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) had a median value of $257.6 million in 2023 and averaged $257.5 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first fell by 2.23% in 2021, then grew by 0.99% in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarterly) stood at $254.3 million in 2021, then rose by 0.96% to $256.7 million in 2022, then climbed by 0.39% to $257.7 million in 2023, then decreased by 0.06% to $257.5 million in 2024, then fell by 0.66% to $256.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $256.4 million for Q3 2025, versus $256.8 million for Q2 2025 and $256.8 million for Q1 2025.